The phase III comparative clinical trial for the investigational Perjeta (pertuzumab) biosimilar HLX11 met the primary endpoint of total pathological complete response rate.
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure.
